Oncolytics Biotech Inc (ONCY) Stock Price, Quote & News

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoin...

Industry: Biotechnology

Sector: Healthcare

Phone: 403 670 7377

Fax: 403 283 0858

Website: oncolyticsbiotech.com

Address:

322 11th Avenue SW, Suite 804, Calgary, Canada

GoPatzGo123 Mar. 20 at 2:46 PM

$ONCY wow look how TIGHT she is. No one selling.

1 · Reply

watchaddict Mar. 20 at 1:46 PM

$ONCY Adding 1k

0 · Reply

saxy4u Mar. 20 at 4:47 AM

$ONCY Potential for Acquisition Strategic Fit: Adlai Nortye is heavily focused on RAS-targeting therapies (such as their pan-RAS inhibitor AN9025). Since pelareorep specifically stimulates RAS-specific T-cell clones to attack mutated cells, it is a perfect biological fit for their existing pipeline. Acquisition Environment: In early 2026, there has been a surge in M&A activity as "Big Pharma" companies race to acquire late-stage assets ahead of a major patent cliff. Analysts have noted that companies like Oncolytics, which have validated Phase 3 data and established manufacturing, are prime targets for buyouts. Oncolytics' U.S. Pivot: It is important to note that Oncolytics recently re-domiciled to Nevada and delisted from the Toronto Stock Exchange to focus entirely on U.S. capital markets. This makes them a more "standard" target for a NASDAQ-listed acquirer like Adlai Nortye (NASDAQ: ANL).

2 · Reply

saxy4u Mar. 20 at 4:14 AM

$ONCY Other April 2026 Milestones While the FDA meeting is about the regulatory path for anal cancer, Oncolytics Biotech is also scheduled for a major scientific presentation in April: AACR Annual Meeting (April 17–22, 2026): The company will present new mechanistic and translational data in San Diego. Focus: This data will highlight how pelareorep acts as an immune-priming backbone, specifically showing how it helps "cold" tumors become "hot" and fosters immune activation in both breast and gastrointestinal cancers.

0 · Reply

saxy4u Mar. 20 at 4:13 AM

$ONCY The mid-April 2026 meeting with the FDA is specifically focused on the Anal Cancer (SCAC) program. Objective of the Meeting The goal is to align with the FDA on the design of a single-arm registrational study for second-line or later Squamous Cell Anal Cancer (SCAC). Small Patient Requirement: Based on strong efficacy data from the GOBLET trial (Cohort 4), the company believes a trial of fewer than 100 subjects will be sufficient to secure FDA approval for this rare cancer. Path to Market: This meeting is a critical step toward an Accelerated Approval pathway, as it seeks to confirm that a small, single-arm study can serve as the basis for a marketing application

0 · Reply

saxy4u Mar. 20 at 3:55 AM

$ONCY just throwing this out there! Adlai had amazing results and is improved in China for PH3 with Pela! https://www.globenewswire.com/news-release/2026/02/12/3236924/0/en/Adlai-Nortye-Announces-First-Patient-Enrolled-in-Global-Phase-1-Trial-of-Pan-RAS-ON-Inhibitor-AN9025-for-Solid-Tumors-Harboring-RAS-Mutations.html

1 · Reply

De_man Mar. 19 at 7:29 PM

$ONCY For the most part it is a done deal and need to put the nol behind us as there is nothing we can do anyway. I tried to do a little more digging and this is what came up. For Oncolytics Biotech Inc., the closest clean proxy to “cumulative net operating loss” is its accumulated deficit (total losses since inception), because detailed NOL carryforward schedules over 20 years are not consistently disclosed publicly year-by-year. Key datapoint As of Dec 31, 2024, the company reported an accumulated deficit of ~$477.7 million (USD) What this means That ~$478M represents the cumulative net losses over the company’s life (which spans more than 20 years). Since Oncolytics has: no sustained revenue, and continuous annual net losses (e.g., ~$31.7M in 2024, ~$27.8M in 2023, ~$24.8M in 2022)

1 · Reply

saxy4u Mar. 19 at 7:21 PM

$ONCY $400 mill NOL is being falsely portrayed! Just over $125 is attached to Canadian Entity which no one said the were abolishing. This could still be intact when company is sold for future tax benefits on Licensing deal or Royalties in Canada.

3 · Reply

De_man Mar. 19 at 5:28 PM

$ONCY yes they price is good right now to buy imo but my big concern is giving up 400 million in nol's for the redomicle move , UNLESS they made the move not knowing this at the time and now too far gone. We will never know as no one would admit that if they made that mistake unless something much bigger going on. But 400 million is nothing small to bring to negotiations. Damn frustrating not knowing.

2 · Reply

saxy4u Mar. 19 at 3:36 PM

$ONCY added another 10k shares! Thanks for the steal!

1 · Reply

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Mar 2, 2026, 9:00 AM EST - 19 days ago

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

Feb 24, 2026, 9:00 AM EST - 25 days ago

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

Feb 4, 2026, 8:50 AM EST - 6 weeks ago

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Jan 15, 2026, 4:01 PM EST - 2 months ago

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

Jan 15, 2026, 11:16 AM EST - 2 months ago

Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript

Jan 12, 2026, 9:00 AM EST - 2 months ago

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Jan 9, 2026, 9:00 AM EST - 2 months ago

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Jan 8, 2026, 9:00 AM EST - 2 months ago

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

Jan 7, 2026, 9:00 AM EST - 2 months ago

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris

Dec 16, 2025, 9:00 AM EST - 3 months ago

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Dec 9, 2025, 6:00 PM EST - 3 months ago

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Nov 20, 2025, 4:05 PM EST - 4 months ago

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

Nov 19, 2025, 9:00 AM EST - 4 months ago

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Oct 28, 2025, 7:30 AM EDT - 5 months ago

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oct 20, 2025, 9:00 AM EDT - 5 months ago

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Sep 29, 2025, 8:30 AM EDT - 6 months ago

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Sep 16, 2025, 7:00 AM EDT - 6 months ago

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Sep 8, 2025, 7:00 AM EDT - 6 months ago

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Sep 2, 2025, 9:10 AM EDT - 7 months ago

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Aug 28, 2025, 8:30 AM EDT - 7 months ago

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Aug 11, 2025, 4:55 PM EDT - 7 months ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Aug 8, 2025, 9:05 AM EDT - 8 months ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Aug 8, 2025, 9:00 AM EDT - 8 months ago

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Aug 5, 2025, 8:30 AM EDT - 8 months ago

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Jul 29, 2025, 8:30 AM EDT - 8 months ago

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Jul 23, 2025, 9:39 AM EDT - 8 months ago

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Jul 22, 2025, 3:32 PM EDT - 8 months ago

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Jul 16, 2025, 8:30 AM EDT - 8 months ago

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Jul 10, 2025, 8:30 AM EDT - 9 months ago

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Jul 8, 2025, 8:30 AM EDT - 9 months ago

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Jun 30, 2025, 7:00 AM EDT - 9 months ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Jun 11, 2025, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

May 23, 2025, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 14, 2025, 7:21 PM EDT - 11 months ago

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:01 PM EDT - 11 months ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 6, 2025, 7:00 AM EDT - 11 months ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 24, 2025, 7:00 AM EDT - 11 months ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 10, 2025, 6:09 PM EDT - 1 year ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Mar 7, 2025, 11:11 AM EST - 1 year ago

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

Mar 7, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Feb 18, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Feb 14, 2025, 5:15 PM EST - 1 year ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Feb 7, 2025, 9:24 PM EST - 1 year ago

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Jan 22, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Jan 15, 2025, 7:02 AM EST - 1 year ago

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Dec 23, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

GoPatzGo123 Mar. 20 at 2:46 PM

$ONCY wow look how TIGHT she is. No one selling.

1 · Reply

watchaddict Mar. 20 at 1:46 PM

$ONCY Adding 1k

0 · Reply

saxy4u Mar. 20 at 4:47 AM

2 · Reply

saxy4u Mar. 20 at 4:14 AM

0 · Reply

saxy4u Mar. 20 at 4:13 AM

0 · Reply

saxy4u Mar. 20 at 3:55 AM

1 · Reply

De_man Mar. 19 at 7:29 PM

1 · Reply

saxy4u Mar. 19 at 7:21 PM

3 · Reply

De_man Mar. 19 at 5:28 PM

2 · Reply

saxy4u Mar. 19 at 3:36 PM

$ONCY added another 10k shares! Thanks for the steal!

1 · Reply

watchaddict Mar. 19 at 3:05 PM

$ONCY 2000 like adding 15% insta soon as dust settles

0 · Reply

aaron03 Mar. 19 at 2:38 PM

$ONCY Same song and dance Thompson = Coffey = Kelly

1 · Reply

De_man Mar. 19 at 1:42 PM

$ONCY Don't read too much into the pr as most of this is old info and in regards to backbone therapy it has been mentioned many times in the past. one example.... Jan. 2024... These data readouts from multiple clinical studies at numerous sites and from diverse cancer indications that are clinically important make a compelling argument for pelareorep as a true backbone immunotherapy with the potential to help countless patients across a range of tumors,” said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. “We believe our cash balance and strong data, supported by our active business development program, position us well for 2024.”

1 · Reply

watchaddict Mar. 19 at 1:40 PM

$ONCY 1000

0 · Reply

PSM_EmpowerTrading Mar. 19 at 1:24 PM

🌅 Watchlist part 2 ✅ $SVRN low $0.20 support, if above $0.40, has potential to $0.50 / $0.55 ✅ $MDAI $1.30 support, if above $1.50, has potential to $1.70 / $1.80 ✅ $SBDS low $5 support, if above $5.50, has potential to $6 / $6.40 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support. 🚨 Avoid chasing long into strength near resistance. ⏳⌛ $BBAI $ONCY still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

m00nsh0t Mar. 19 at 1:10 PM

$ONCY NR out today regarding abstracts at AACR sighting PELA as a foundational backbone in immunotherapy combinations. I think notable was the first to start calling it a backbone and now the company is calling it that.

1 · Reply

PSM_EmpowerTrading Mar. 19 at 2:03 AM

🌅 Watchlist part 2 ✅ $SVRN low .30 support, if above .40, have potential to .50/.55 ✅ $SER mid 1.50 support, if above 2, have potential to 2.40/.60 ✅ $SUNE 1.50 support, if above 2, have potential to 2.50/.80 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⏳ $BBAI $ONCY still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

1 · Reply

PSM_EmpowerTrading Mar. 18 at 1:27 PM

🌅 Watchlist part 3 ✅ $TURB low 3 support, if above 3.30, have potential to 3.50/.80 ✅ $HITI mid 2.50 support, if above 2.85, have potential to 3/3.20 ✅ $BIAF low 2.30 support, if above 2.50, have potential to 2.70/.80 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⌛ $FATE $ONCY still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

GoPatzGo123 Mar. 18 at 12:45 PM

$ONCY Regarding the next significant catalyst we are anticipating, could you please clarify what it might be? Are we looking at patents or perhaps phase trials? The share price has unfortunately not shown any movement in 2026, and we are already three months into the year.

2 · Reply

PSM_EmpowerTrading Mar. 18 at 4:02 AM

🌅 Watchlist part 2 ✅ $HIT.X low $2 support, if above $2.30, have potential to $2.60/$2.70 ✅ $DVLT low $0.80 support, if above $1.00, have potential to $1.20/$1.30 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⌛ $FATE $ONCY still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

saxy4u Mar. 17 at 9:23 PM

$ONCY oh no 7mill shorts! Daily volume falling 362k today, 19 days to cover! April 1st is coming!!!

1 · Reply

GoPatzGo123 Mar. 17 at 7:09 PM

$ONCY balls out!!!

1 · Reply

Market Cap	101.95M
Revenue (ttm)	0.00
Net Income (ttm)	-23.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	540,700
Avg Vol	1,505,842
Day's Range	N/A - N/A
Shares Out	106.15M
Stochastic %K	10%
Beta	0.92
Analysts	Strong Sell
Price Target	$5.01